Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis. 2003

Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland. vappu.siren@helsinki.fi

Intimal hyperplasia and subsequent thrombotic occlusions limit the success of vascular reconstructive procedures. Plasminogen activation in situ may be an important factor affecting re-stenosis of the graft. Tissue specimens from eight patients with failing or failed infra-inguinal vein bypasses and three specimens from normal veins were harvested to study urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) by in situ hybridization and immunohistochemistry. The possible presence of thrombi was monitored by platelet and fibrin-specific stainings. In occluded grafts, platelet endothelial cell adhesion molecule (PECAM-1) antibody stained the thrombi but not the endothelial area, indicating the absence of endothelium. Platelet glycoprotein (GP) IIb/IIIa co-localized with PECAM-1 and, furthermore, GP IIb/IIIa staining was positive on the vein walls with thrombi and to some extent in the grafts without thrombi. PAI-1 and u-PA were uniformly upregulated in intimal thickening in grafts without thrombus. In organized thrombi, enhanced u-PA, t-PA and PAI-1 reactivity was detected in the ingrowing subendothelium. In non-occluded grafts with small thrombi, u-PA expression was enriched beneath microthrombi co-localizing with the graft wall injury, while PAI-1 was scattered in the (sub)endothelium. We conclude that fibrinolytic system is upregulated at sites of graft stenosis, and local proteolytic degradation of the graft wall associates with thrombus formation.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D003251 Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions. Stenosis,Stricture,Constriction, Pathological,Pathologic Constriction,Constrictions, Pathologic,Pathologic Constrictions,Pathological Constriction,Stenoses,Strictures
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D005260 Female Females
D006083 Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts. Graft Restenosis, Vascular,Vascular Graft Occlusion,Vascular Graft Restenosis,Graft Restenoses, Vascular,Occlusion, Vascular Graft,Restenosis, Vascular Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
January 1997, Oncology reports,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
May 2000, Pathology international,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
March 1991, The Journal of biological chemistry,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
September 1998, Journal of gastroenterology and hepatology,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
January 1995, Journal of clinical laboratory analysis,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
September 2007, Histology and histopathology,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
January 1995, Annals of the New York Academy of Sciences,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
October 1997, Molecular and cellular endocrinology,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
January 2002, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Vappu Sirén, and Petteri Kauhanen, and Olli Carpén, and Michael Luther, and Mauri Lepäntalo, and Antti Vaheri, and Riitta Lassila
July 1988, European journal of biochemistry,
Copied contents to your clipboard!